McKesson To Spin-Off Its Medical-Surgical Solutions Business

(AP Photo/Paul Sakuma, File)
Deal OverviewOn May 8, 2025, McKesson Corporation (NYSE: MCK, $682.28, Market Capitalization: $85.4 billion), a diversified healthcare services company, announced its intention to separate its Medical-Surgical Solutions segment into an independent company (NewCo) (for more information, visit spinoffresearch.com). McKesson is committed to exploring all opportunities to execute a separation in a manner that maximizes shareholder value and anticipates providing more information as appropriate on the form and timing as the process progresses. On May 1, 2025, the Board of Directors of McKesson Corporation declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on July 1, 2025, to stockholders of record on June 2, 2025.
McKesson Price Performance Spin-Off Details and Top 5 Shareholders
Deal Rationale
McKesson's strategic focus on disciplined portfolio management involves continuous evaluation of its business segments to ensure alignment with its growth priorities and optimize capital allocation. This strategic approach has previously led to transformative actions such as the divestiture of Change Healthcare in 2020 and the divestiture of its European and Canadian retail businesses, which have unlocked considerable value for shareholders. Moreover, Change Healthcare was fully acquired by UnitedHealth in 2022. As a continuation of this strategy, McKesson has announced its intent to separate the Medical-Surgical segment into an independent company. McKesson believes a separation of the Medical-Surgical Solutions business will further enhance the strategic opportunity and operational focus of both companies and unlock value for McKesson shareholders. A separation would result in two well-capitalized, world-class companies, well-positioned to pursue their respective strategic growth priorities. The separation advances McKesson and NewCo's ability to create value for customers, partners, patients, and shareholders with increased investment and dedicated capital allocation.
Post-spin-off, McKesson will continue to focus on its capital deployment priorities on opportunities that best align with its long-term enterprise strategies. McKesson will advance its portfolio to focus investment on higher growth, higher margin opportunities in Oncology and Biopharma Solutions, unlocking substantial value for stakeholders. In order to strengthen its core operations, McKesson acquired Rx Savings Solutions in late 2022 to enhance biopharma and payer connectivity with patients and formed SCRI Oncology with HCA Healthcare to expand access to cancer clinical trials. McKesson holds a 51% controlling interest in SCRI, reported under its U.S. Pharmaceutical segment. Additionally, the company announced plans to acquire a controlling stake in Core Ventures, a business services organization established by Florida Cancer Specialists, with the deal expected to close on June 2, 2025.
Moreover, the Medical-Surgical Solutions segment, which represents only 3.2% of the total company's revenue, has seen sluggish growth since 2020 due to a shift in demand, lower volumes, supply chain disruption and also due to post-pandemic normalization. Post-separation, the new Medical-Surgical Solutions company (NewCo) would be a differentiated medical surgical supply and solutions company with a compelling leadership position, attractive margins, and potential for growth acceleration across all the alternate sites of care markets. With FY25 revenue of around $11.4 billion, the spin off is designed to sharpen McKesson's focus on pharmaceutical and specialty services, especially in high-growth areas like oncology, while allowing both entities to pursue tailored growth strategies.
McKesson Corporation, founded in 1833, is headquartered in Irving, Texas. With a legacy spanning over 190 years, McKesson plays a critical role in delivering pharmaceuticals, medical supplies, and health IT solutions across North America and selected international markets. Under the leadership of CEO Brian S. Tyler, the company trades on the NYSE under the ticker symbol MCK. The company operates through three key business segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International.
Key Data
U.S. Pharmaceutical Segment (91.3% of FY25 sales)
U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter (OTC) pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, and alternate sites) and provides consulting, outsourcing, technological, and other services.
Prescription Technology Solutions Segment (1.5% of FY25 sales)
Prescription Technology Solutions (RxTS) connects patients, pharmacies, providers, health plans, pharmacy benefit managers, and biopharma companies to improve medication access across the healthcare system. Integrated with most EHRs, 50,000+ pharmacies, 950,000 providers, and supporting 650+ biopharma brands, RxTS offers end-to-end solutions from prescription to therapy. Its services include affordability support, price transparency, benefit insights, dispensing support, logistics, and distribution. In the past year, RxTS saved patients over $10 billion, prevented 12 million abandoned prescriptions, and enabled medication access over 100 million times, reinforcing its vital healthcare role.
Medical-Surgical Solutions (to be spun-off) (3.2% of FY25 sales)
The Medical-Surgical Solutions segment provides medical-surgical supply distribution,
logistics, and other services to healthcare providers, including physician offices, surgery
centres, nursing homes, hospital reference labs, and home health care agencies. The
segment offers more than 245,000 national brand medical-surgical products as well as
McKesson's line of high-quality products through a network of distribution centres in
the U.S. With FY25 revenue of around $11.4 billion, the spin-off is designed to sharpen
McKesson's focus on pharmaceutical and specialty services, especially in high-growth
areas like oncology, while allowing both entities to pursue tailored growth strategies.
International segment (4.0% of FY25 sales)
McKesson's International segment includes operations in Canada and Norway. McKesson Canada is one of the country's largest pharmaceutical wholesale and retail distributors, serving pharmacies, hospitals, long-term care centres, and clinics through a national distribution network. Beyond logistics, it offers automation and technology solutions to retail and hospital clients. McKesson Canada also delivers specialty health services and biopharma support, including personalized patient programs and a national network of specialty pharmacies. It operates INVIVA, Canada's first and largest accredited private infusion clinic network, and owns PDCI, the country's leading market access consultancy. These services help biopharma manufacturers introduce new products to market while enhancing patient care and access across Canada's healthcare system.
Revenue
4Q25
For 4Q25, the company recorded revenues of $90.8 billion, up by 18.9% YoY compared to $76.4 billion in 4Q24, primarily driven by growth in the U.S. Pharmaceutical segment, due to increased prescription volumes from retail national customers and growth in the distribution of specialty products, including higher volumes in oncology. Operating Income for the quarter was $1.6 billion, up by 30.8% YoY with a margin of 1.8%, up by 20 bps. Adjusted operating income was $1.5 billion, up by 23.5% YoY with a margin of 1.7%, flat as compared to the prior year. The growth in operating income benefited from growth across all operating segments, including strong oncology and other specialty provider volumes, the onboarding of a new strategic customer in 2Q, and increased demand for access solutions in the Prescription Technology Solutions segment. Net income for the period was $1.31 billion, up by 57.3% YoY, while adjusted net income was $1.27 billion, up by 56.7% YoY. Similarly, Diluted EPS on a reported basis was $10.01 per share, up by 66.3%, while adjusted diluted EPS was $10.12 per share, up by 63.8% YoY. The growth in Net income and EPS was driven by a lower effective tax rate and strong operational growth across the business.
FY25
For FY25, the company recorded revenues of $359.1 billion, up by 16.2% YoY compared to $309.0 billion in FY24, driven by broad-based operational strength across the business, including the onboarding of a new strategic customer in the U.S. Pharmaceutical segment. Operating Income for the year was $4.4 billion, up by 13.1% YoY with a margin of 1.2%, down 10 bps compared to the prior year. On the other hand, the adjusted operating income was $5.6 billion, up by 14.6% YoY with a margin of 1.6%, which was flat compared to the prior year. The growth in operating income was led by a double-digit growth in the U.S. Pharmaceutical and Prescription Technology Solutions segments and Canadian business within International. Excluding the impact of net gains related to McKesson Ventures, operating profit increased 12% YoY compared to the prior year, well above MCK's long-range target. Net income for the period was $3.3 billion, up by 9.8% YoY, while adjusted net income was $4.2 billion, up by 15.1% YoY. Similarly, diluted EPS on a reported basis was $25.72 per share, up by 14.9%, while adjusted diluted EPS was $33.05 per share, up by 20.4% YoY. Growth in Net income and EPS was driven by strong operational growth across the business and a lower share count.
FY26 Outlook:
McKesson has issued fiscal FY26 guidance for Adjusted Earnings per Diluted Share in the range of $36.75 to $37.55, reflecting an expected growth of 11% to 14% year-over year. Excluding net gains from McKesson Ventures' equity investments in FY25, the projected growth is expected to increase 13% to 16%. While the company does not forecast GAAP earnings per share, it has reaffirmed its long-term Adjusted EPS growth target of 12% to 14% and updated the long-term Adjusted Segment Operating Profit growth target for its U.S. Pharmaceutical segment from 5%–7% to a revised range of 6%–8%.
Long-Term Growth Targets
McKesson continues to strengthen its portfolio of differentiated assets and capabilities, advancing health outcomes for all. As a result of continued, consistent, strong execution against its strategic initiatives, McKesson is updating and reaffirming the following long-term growth targets:
• Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 12% to 14%.
• Updating U.S. Pharmaceutical long-term Adjusted Segment Operating Profit growth target to 6% to 8% from the previous range of 5% to 7%.
• Reaffirming Prescription Technology Solutions long-term Adjusted Segment Operating Profit growth target of 11% to 12%.
Company DescriptionMcKesson Corporation (Parent)
McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. The company is engaged in the distribution of pharmaceuticals and medical products, as well as providing technology enabled services that support the clinical and financial outcomes of healthcare providers and payers. McKesson operates through several business segments, including U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International. Its extensive distribution network and logistics capabilities serve a wide array of customers, including hospitals, pharmacies, physicians' offices, long-term care facilities, and home health agencies. McKesson's U.S. Pharmaceutical segment distributes branded, generic, and over-the-counter drugs to retail pharmacies and institutional healthcare providers. Its international segment serves healthcare markets in Canada and Europe. The company leverages advanced analytics, automation, and digital capabilities to streamline operations and enhance healthcare delivery outcomes across geographies. McKesson has operations in more than a dozen countries and employs over 45,000 people worldwide. The company continues to invest in innovative solutions and partnerships to improve patient access, support value-based care models, and reduce the total cost of care. For FY25, McKesson reported Consolidated revenues of $359.1 billion, highlighting its scale and impact in the global healthcare ecosystem.
Medical-Surgical Solutions (Spin-Off)
The Medical-Surgical Solutions division handles the distribution of medical-surgical supplies, logistics, and related services to various healthcare providers, such as clinics, surgical centres, elder care facilities, hospital labs, and home healthcare agencies. It delivers over 245,000 branded medical-surgical products, along with McKesson's proprietary high-quality items, through a network of U.S.-based distribution centres. On May 8, 2025, McKesson announced plans to separate this segment into a standalone company, temporarily referred to as 'NewCo.' The business generated $11.4 billion in revenue during FY25.
Organization Structure

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

37 minutes ago

• Yahoo

Comtech Rejoins iCERT, Deepening Commitment to Public Safety Innovation

Renewed Membership Reinforces Public Safety Commitment and Expands Advocacy Platform CHANDLER, Ariz., June 20, 2025--(BUSINESS WIRE)--Jun. 20, 2025-- Comtech Telecommunications Corp. (NASDAQ: CMTL) ("Comtech" or the "Company"), a global communications technology leader, today announced that its Terrestrial & Wireless Networks ("T&W") business segment has rejoined the Industry Council for Emergency Response Technologies, Inc. ("iCERT"). Founded in 2005, iCERT is a commercial sector trade association that brings together leading technology companies to drive innovation, shape effective policy, and promote open standards that improve public safety and emergency response. This return to iCERT is part of a series of strategic moves by the T&W business segment, including the launch of Allerium Mira - a cloud-native call handling platform designed to simplify complexity and support evolving 9-1-1 needs. Together, these efforts reflect a renewed commitment to public safety and essential service providers, backed by the same trusted team, proven solutions, and industry-wide support. "We're excited to collaborate with iCERT as it expands its focus on key issues and innovations in emergency communications," said Susan Ornstein, Senior Director of Legal & Regulatory Affairs of Comtech T&W, who joined the association's board of directors earlier this month. "Under its new leadership, iCERT is amplifying the voice of its members on public policy issues and engaging partner associations like NASNA, NENA, and APCO to advance shared priorities across the public safety community. Together with iCERT, Comtech is well positioned to address pressing public safety and regulatory matters, and advocate for federal funding, legislation, and FCC policy updates." "Few organizations have meant as much to me throughout my career as iCERT," said Jeff Robertson, President of Comtech T&W. "Twenty years ago, I worked alongside two industry visionaries to establish this organization with the shared goal of fostering collaboration between the public and private sectors. I was privileged to serve as iCERT's inaugural executive director and have remained a strong advocate of its mission throughout my career. Seeing our company rejoin the iCERT community is especially meaningful. Comtech is committed to delivering results that help communities become safer, more connected, and resilient, and iCERT is a vital partner in advancing that work." "iCERT stands committed to propelling public safety forward, facilitating collaboration among its member base and industry stakeholders, and creating an environment that fosters innovation and progress," said Don Brittingham, Interim Executive Director of iCERT. "Members like Comtech play a vital role in strengthening the organization's depth and breadth of experience across the full public safety call flow. I am excited to welcome Jeff Robertson and his team back to iCERT and look forward to empowering public safety together." About Comtech Comtech Telecommunications Corp. is a leading provider of satellite and space communications technologies; terrestrial and wireless network solutions; Next Generation 9-1-1 (NG9-1-1) and emergency services; and cloud native capabilities to commercial and government customers around the world. Through its culture of innovation and employee empowerment, Comtech leverages its global presence and decades of technology leadership and experience to create some of the world's most innovative solutions for mission-critical communications. For more information, please visit About iCERT iCERT—The Industry Council for Emergency Response Technologies—is the only industry trade association focused exclusively on emergency response technologies and related equipment, systems, and services. iCERT is dedicated to improving public safety through innovation. For more information, please visit Forward-Looking Statements Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results and performance could differ materially from such forward-looking information. The Company's Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such Securities and Exchange Commission filings. View source version on Contacts Investor Relations Maria Ceriello631-962-7102investors@ Media Contact Jamie

Bloomberg

43 minutes ago

• Bloomberg

Rebecca Shi on ICE Raids Scaring Essential US Workers

Rebecca Shi, American Business Immigration Coalition Executive Director, discusses the impact ICE raids are having on the US labor force and shares her thoughts on whether or not the deportations themselves or the fear the deportations are instilling on workers are putting more stress on the job market. She speaks with Joe Mathieu and Tyler Kendall on the late edition of Bloomberg's "Balance of Power." (Source: Bloomberg)

Yahoo

44 minutes ago

• Yahoo

Trade Idea Moves Twins' Byron Buxton to Phillies

Trade Idea Moves Twins' Byron Buxton to Phillies originally appeared on Athlon Sports. The Boston Red Sox may have started a new trend in their trade of Rafael Devers: using the trade market to offload a superstar previously signed to lengthy, big-money deals. Advertisement In 2023, Devers signed a 10-year, $313.5 million extension to his already-existing contract, which was set to expire at the end of the season. The financial commitments the Red Sox had to the slugger did not deter them from moving him just one and a half years into the deal, as they traded him to the San Francisco Giants. Such a transaction has only happened one other time in MLB history – when the Miami Marlins traded Giancarlo Stanton to the New York Yankees three years into a 13-year, $325 million deal in 2018. That beckons a double-barreled question: When will this kind of deal happen again, and who will it involve? According to Bleacher Report's Zachary D. Rymer, the Minnesota Twins and Philadelphia Phillies should field calls to each other about All-Star outfielder Byron Buxton, a player who also won a Gold Glove Award in 2017. Buxton is currently in year four of a seven-year, $100 million deal with the Twins. Jul 31, 2024; New York City, New York, USA; Minnesota Twins center fielder Byron Buxton (25) celebrates his solo home run against the New York Mets with teammates in the dugout during the second inning at Citi Field. Mandatory Credit: Brad Penner-USA TODAY Sports © Brad Penner-USA TODAY Sports "Buxton's long-term future... remains suspect. He is keeping up his act as a two-way star when he does play, but he's a 31-year-old with one of the most cluttered injury histories in recent memory. And as such, the Twins should be wondering if this is their last best chance to sell high on him," Rymer wrote. Advertisement "Because he has full no-trade protection, he'll only go anywhere if he wants to. But if the Twins present him with a chance to spend the rest of his prime with a proper World Series contender, it could be hard for him to turn it down." Rymer sees the Phillies as an ideal trade destination for Buxton because he would fulfill a need the team has been missing for years. "Not since the early days of Odúbel Herrera's career have the Phillies had a reliable regular in center field, much less a star. They have managed to succeed despite this, but that should raise questions about how far they could go if they actually went out and got a star to roam the middle of their outfield," Rymer wrote. "A trade for Buxton would fit the bill, and such a deal would be right up Dave Dombrowski's alley." Advertisement Through 57 games this season, Buxton is hitting .280 with 15 home runs, 45 RBIs, 12 stolen bases, a .898 OPS, and 2.6 WAR (according to Baseball Reference). Related: Phillies' Cristopher Sánchez Reflects on Best Start of 2025 This story was originally reported by Athlon Sports on Jun 20, 2025, where it first appeared.